Imfinzi approved in the EU as first and only immunotherapy for limited-stage small cell lung cancer

AstraZeneca·Mar 17

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Imfinzi has been approved in the eu for use in certain types of cancer. However, there is uncertainty about which specific types of cancer it has been approved for, with some reports indicating it is for limited-stage small cell lung cancer, while others suggest it is for early gastric and gastroesophageal cancers. The medication has also received approval in the us, but the specific details of this approval are not consistent across reports.

Full coverage

Imfinzi approved in the EU as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers

AstraZeneca·Mar 16

AstraZeneca’s Imfinzi wins EU-first immunotherapy approval in early GI cancers

European Pharmaceutical Review·Mar 24

Imfinzi Approved in the EU as First Perioperative Immunotherapy for Early Gastric and GEJ Cancers

Oncodaily·Mar 18

Imfinzi approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer.

AstraZeneca·May 28

EU Approves AstraZeneca's Imfinzi Combo as First Perioperative Treatment for Early Gastric Cancer

Yahoo Finance UK·Mar 16

AstraZeneca’s Imfinzi approved in EU for early gastric and gastro-oesophageal cancers

PMLiVE·Mar 16

AstraZeneca’s Imfinzi Wins EU Approval for Early Gastric/GEJ Cancer

Oncodaily·Mar 19

Imfinzi approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers

AstraZeneca·Nov 25

View original report at AstraZeneca ↗

Fetching the latest headlines…